Forbes April 14, 2021
Amy Feldman

Sajith Wickramasekara was just 24 when he made the cut for Forbes 30 Under 30 list for his biotech R&D startup Benchling. Today, Wickramasekara joins the ranks of unicorn founders as Benchling hits a $4 billion valuation. That valuation – nearly five times what it was worth last May – comes as the company raised $200 million led by Sequoia Capital Global Equities.

“The industry tail winds have never been stronger,” Wickramasekara, now 30, told Forbes. “It’s not just happening in medicine. It’s also diagnostics, agriculture, food, consumer packaged goods. I look at it as the 4th Industrial Revolution, and I genuinely believe it is going to rewrite life as we know it.”

The new investment brings Benchling total funding to $350 million, and puts...

Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Biotech and medical device companies raise $913M in a five-IPO week
Evolution Of The Biotech IPO Markets From Busted To Booming
Genomics Funding Is On Track To Break Records As The Sector Matures
The Record-Breaking Biotech Funding Tsunami Of 1H2020
eMerge Network Gets Funding to Improve Genomic Risk Assessments for Diverse Populations

Today's Sponsors

Curation Health

Today's Sponsors


Today's Sponsor